文献速递临床试验与 GCP流行病学与生物统计

COVID-19 研究响应需更好协调与合作:注册试验的动态映射

Research response to coronavirus disease 2019 needed better coordination and collaboration: a living mapping of registered trials.
PubMed 文献 · J Clin Epidemiol · 2020-10-21

该研究对 WHO 国际临床试验注册平台进行每周系统检索,动态映射 COVID-19 随机对照试验的注册情况。截至 2020 年 8 月 12 日共注册 1,568 项试验,多数评估治疗且注册时间在疫情高峰之后,研究问题存在冗余且样本量偏小。

要点

  • 截至 2020 年 8 月 12 日全球注册 1,568 项 COVID-19 随机对照试验。
  • 多数试验评估治疗(1,333 项,85%),预防策略仅 223 项(14%)。
  • 试验注册常在疫情高峰后,研究问题存在冗余且样本量偏小。

核心结论

  • COVID-19 试验样本量相对较小,研究问题存在一定冗余。
  • 多数试验在疫情第一波高峰过后才注册。

研究设计与样本

  • 对 WHO 国际临床试验注册平台进行动态映射,每周系统检索所有 COVID-19 预防与治疗随机对照试验。
  • 建立公开交互式映射工具(https://covid-nma.com)可视化所有注册试验。

主要发现

  • 截至 2020 年 8 月 12 日,全球注册 1,568 项 COVID-19 试验。
  • 各国首例病例记录至首项随机对照试验注册的中位延迟为 47 天(Q1-Q3:33-67;范围 15-163)。
  • 注册试验数最多的 9 个国家中,多数试验在疫情高峰后注册(从意大利的 100% 到美国的 38%)。
  • 多数试验评估治疗(1,333 项;85%),仅 223 项(14%)评估预防策略,12 项为急性期后干预。
  • 254 项试验计划评估不同羟氯喹方案,预期样本量合计 110,883 例患者。

临床怎么用

  • 提示研究者在疫情早期即应协调试验注册与研究问题,避免冗余。
  • 试验设计需考虑足够样本量以回答关键临床问题。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Researchers worldwide are actively engaging in research activities to search for preventive and therapeutic interventions against coronavirus disease 2019 (COVID-19). Our aim was to describe the planning of randomized controlled trials (RCTs) in terms of timing related to the course of the COVID-19 epidemic and research question evaluated. STUDY DESIGN AND SETTING: We performed a living mapping of RCTs registered in the WHO International Clinical Trials Registry Platform. We systematically search the platform every week for all RCTs evaluating preventive interventions and treatments for COVID-19 and created a publicly available interactive mapping tool at https://covid-nma.com to visualize all trials registered. RESULTS: By August 12, 2020, 1,568 trials for COVID-19 were registered worldwide. Overall, the median ([Q1-Q3]; range) delay between the first case recorded in each country and the first RCT registered was 47 days ([33-67]; 15-163). For the 9 countries with the highest number of trials registered, most trials were registered after the peak of the epidemic (from 100% trials in Italy to 38% in the United States). Most trials evaluated treatments (1,333 trials; 85%); only 223 (14%) evaluated preventive strategies and 12 postacute period intervention. A total of 254 trials were planned to assess different regimens of hydroxychloroquine with an expected sample size of 110,883 patients. CONCLUSION: This living mapping analysis showed that COVID-19 trials have relatively small sample size with certain redundancy in research questions. Most trials were registered when the first peak of the pandemic has passed.

来源:J Clin Epidemiol,查看原文。版权归原作者所有。

引用

  1. Nguyen VT, Rivière P, Ripoll P, et al. Research response to coronavirus disease 2019 needed better coordination and collaboration: a living mapping of registered trials. J Clin Epidemiol. 2020. PMID: 33096223. doi:10.1016/j.jclinepi.2020.10.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。